Stock Events

Stock Events

Pharnext 

$249,999,999,000
25
+$24+0% Friday 20:00

Statistics

Day High
0
Day Low
0
52W High
249,999,999,000
52W Low
0
Volume
100
Avg. Volume
0
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

19
FEB 27
Dividend Ex
Estimated
 

Dividends

0%Dividend Yield
Feb 26
$0.24
Feb 25
$0.21
Feb 24
$0.22
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

4JunExpected
Q3 2022
Q3 2023
Q1 2024
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-25,030.79%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
174,829.17Revenue
-43.76MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PNEXF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases, directly competing with Pharnext's Charcot-Marie-Tooth disease treatment.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, overlapping with Pharnext's genetic disorder treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, competing in the genetic disorder space.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in creating treatments for cystic fibrosis and other genetic disorders, competing with Pharnext's focus.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics works on treatments for genetic disorders, directly competing with Pharnext's drug development focus.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the genetic and rare disease market.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Pharnext's approach to treating genetic disorders.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for neurological and genetic disorders, competing on multiple fronts with Pharnext.

About

Biotechnology
Health Technology
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Show more...
CEO
Mr. Daniel E. Cohen M.D., Ph.D.
Country
FR
ISIN
FR0011191287

Listings

0 Comments

Share your thoughts

FAQ

What is Pharnext stock price today?▼
The current price of PNEXF is $249,999,999,000 USD — it has increased by +0% in the past 24 hours. Watch Pharnext stock price performance more closely on the chart.
What is Pharnext stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pharnext stocks are traded under the ticker PNEXF.
What were Pharnext earnings last quarter?▼
PNEXF earnings for the last quarter are -0.35 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pharnext revenue for the last year?▼
Pharnext revenue for the last year amounts to 174,829.17 USD.
What is Pharnext net income for the last year?▼
PNEXF net income for the last year is -43.76M USD.
In which sector is Pharnext located?▼
Pharnext operates in the Health Care sector.
When did Pharnext complete a stock split?▼
The last stock split for Pharnext was on February 15, 2024 with a ratio of 1:10000.
Where is Pharnext headquartered?▼
Pharnext is headquartered in Suresnes, FR.